NCT05091047View on ClinicalTrials.gov

Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Neuropathy
Interventions
DEVICE

Erchonia EVRL

42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.

Trial Locations (1)

32904

Erchonia, Melbourne

Sponsors
All Listed Sponsors
lead

Erchonia Corporation

INDUSTRY